Literature DB >> 22174401

Impaired vascular responses to relaxin in diet-induced overweight female rats.

Joris van Drongelen1, Arianne van Koppen, Jeanne Pertijs, Jonathan H Gooi, Laura J Parry, Fred C G J Sweep, Frederik K Lotgering, Paul Smits, Marc E A Spaanderman.   

Abstract

Relaxin mediates renal and mesenteric vascular adaptations to pregnancy by increasing endothelium-dependent vasodilation and compliance and decreasing myogenic reactivity. Diet-induced overweight and obesity are associated with impaired endothelial dysfunction and vascular remodeling leading to a reduction in arterial diameter. In this study, we tested the hypothesis that local vascular responses to relaxin are impaired in diet-induced overweight female rats on a high-fat cafeteria-style diet for 9 wk. Rats were chronically infused with either relaxin or placebo for 5 days, and vascular responses were measured in isolated mesenteric arteries and the perfused kidney. Diet-induced overweight significantly increased sensitivity to phenylephrine (by 17%) and vessel wall thickness, and reduced renal perfusion flow (RPFF; by 16%), but did not affect flow-mediated vasodilation, myogenic reactivity, and vascular compliance. In the normal weight rats, relaxin treatment significantly enhanced flow-mediated vasodilation (2.67-fold), decreased myogenic reactivity, and reduced sensitivity to phenylephrine (by 28%), but had no effect on compliance or RPFF. NO blockade by l-NAME diminished most relaxin-mediated effects. In diet-induced overweight rats, the vasodilator effects of relaxin were markedly reduced for flow-mediated vasodilation, sensitivity to phenylephrine, and myogenic response compared with the normal diet rats, mostly persistent under l-NAME. Our data demonstrate that some of the vasodilator responses to in vivo relaxin administration are impaired in isolated mesenteric arteries and the perfused kidney in diet-induced overweight female rats. This does not result from a decrease in Rxfp1 (relaxin family peptide receptor) expression but is likely to result from downstream disruption to endothelial-dependent mechanisms in diet-induced overweight animals.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22174401     DOI: 10.1152/japplphysiol.00470.2011

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  8 in total

Review 1.  Vascular actions of relaxin: nitric oxide and beyond.

Authors:  C H Leo; M Jelinic; H H Ng; S A Marshall; J Novak; M Tare; K P Conrad; L J Parry
Journal:  Br J Pharmacol       Date:  2016-09-30       Impact factor: 8.739

2.  Human relaxins (RLNH1, RLNH2), their receptor (RXFP1) and fetoplacental growth.

Authors:  Kelly Yamasato; Pai-Jong Stacy Tsai; James Davis; Sandra Y Yamamoto; Gillian D Bryant-Greenwood
Journal:  Reproduction       Date:  2017-05-03       Impact factor: 3.906

3.  Localization of relaxin receptors in arteries and veins, and region-specific increases in compliance and bradykinin-mediated relaxation after in vivo serelaxin treatment.

Authors:  Maria Jelinic; Chen-Huei Leo; Emiel D Post Uiterweer; Shaun L Sandow; Jonathan H Gooi; Mary E Wlodek; Kirk P Conrad; Helena Parkington; Marianne Tare; Laura J Parry
Journal:  FASEB J       Date:  2013-09-13       Impact factor: 5.191

Review 4.  Increased risk for the development of preeclampsia in obese pregnancies: weighing in on the mechanisms.

Authors:  Frank T Spradley; Ana C Palei; Joey P Granger
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2015-10-07       Impact factor: 3.619

5.  Time-dependent activation of prostacyclin and nitric oxide pathways during continuous i.v. infusion of serelaxin (recombinant human H2 relaxin).

Authors:  C H Leo; M Jelinic; H H Ng; M Tare; L J Parry
Journal:  Br J Pharmacol       Date:  2016-02-17       Impact factor: 8.739

6.  Acute intravenous injection of serelaxin (recombinant human relaxin-2) causes rapid and sustained bradykinin-mediated vasorelaxation.

Authors:  Chen Huei Leo; Maria Jelinic; Helena C Parkington; Marianne Tare; Laura J Parry
Journal:  J Am Heart Assoc       Date:  2014-02-28       Impact factor: 5.501

7.  A vasoactive role for endogenous relaxin in mesenteric arteries of male mice.

Authors:  Chen Huei Leo; Maria Jelinic; Jon H Gooi; Marianne Tare; Laura J Parry
Journal:  PLoS One       Date:  2014-09-22       Impact factor: 3.240

Review 8.  Relaxin as a Therapeutic Target for the Cardiovascular Complications of Diabetes.

Authors:  Hooi Hooi Ng; Chen Huei Leo; Laura J Parry; Rebecca H Ritchie
Journal:  Front Pharmacol       Date:  2018-05-15       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.